Xueba’s medical black technology system

Chapter 187 Meeting of Pharmaceutical Giants
Lu Liang didn't expect that he would meet Azzoli by such a coincidence while eating food.

After being stunned for a moment, Lu Liang nodded: "Thank you."

Zoli then said: "Actually, what surprised me the most was the inspiration you shared after answering Brennan's question. It really provided me with a lot of inspiration."

"After all, if you don't share this inspiration, you should still be able to make a lot more achievements."

Azzoli couldn't help but sigh: "If it were me, I wouldn't be willing to share such a good idea."

Lu Liang smiled and replied: "Actually, these immune checkpoint antibodies are composed of three parts, namely COR1, CDR2 and CDR3 regions. Most antibodies can only play a major role in the three regions. One to two CDR regions.”

"My bispecific antibody just grafts the effective CDR regions of two different antibodies together."

When he said this, Lu Liang paused, and then he continued: "In a sense, it is not too complicated. Even if I don't say it, other scholars will soon think of this."

Azzoli nodded, and then said: "Despite what I said, I still have to thank you. At least now I have a lot of ideas in my mind, and I can't wait to try it out."

"This may help with other cancers."

Lu Liang frowned and thought: "What should I say? It depends on whether the expression of immune checkpoints is high or not. It does not mean that it will be effective if used. After all, TIGIT is only a receptor that is highly expressed in lung cancer. Other That’s not necessarily the case in cancer.”

At this moment, the exchange between Lu Liang and Azzoli also attracted the attention of scholars passing nearby.

"Who is this person? Why is he communicating with Azzoli? And isn't Azzoli usually disgusted by others communicating with him during his meal time?"

"He is Lu Liang. I asked you to come with me to the joint meeting to listen to the report. You have to go to the Radiation Oncology Lecture Hall. You don't know what you missed."

"Stop it, I'm starting to regret it now."

After finishing the meal, Lu Liang returned to the lecture hall.

The subsequent meeting went much smoother, and nothing unexpected happened.

In this way, the two-day Asian Lung Cancer Conference came to a successful conclusion.

After the meeting, Lu Liang immediately booked a flight back to school.

However, he was the only one who bought a ticket to go back.

Ji Hong will stay in Yangcheng for another day because of the invitation of other scholars. Wang Wentao also plans to experience the humanistic scenery of Yangcheng, so he will go back the next day.

In other words, except for Lu Liang who returned to school on the day the meeting ended, Ji Hong and Wang Wentao both chose to return the next day.

Lu Liang had no choice but to carry his luggage and rush to the airport alone.

Meanwhile, it's twelve o'clock New York time.

At the door of the conference room, a man was staring at the news on his mobile phone screen.

This news report is exactly what happened at the Asian Lung Cancer Conference.

Especially the report about Lu Liang, the news devoted a large part of it to reporting on how Brennan made things difficult, and then things turned around.

This made the man frown slightly.

Suddenly, a call came in. The man glanced at the phone number and then answered the call.

It was Cai Tao's voice that came from the other end of the phone: "Boss, he didn't agree."

The person Cai Tao was talking about was naturally referring to Lu Liang.

"I understand, please come back."

The man said lightly, without too much surprise or surprise in his tone, as if he had already expected such a result.

Cai Tao hesitated for a moment: "How about I try harder?"

But Cai Tao's proposal was directly rejected by the man: "No need, this cannot be achieved with hard work."

"Tao, there is a saying in your country that says people who are different cannot work together. What he pursues is different from what we pursue. We are destined not to get together, so there is no need to waste time on such things."

Having said this, the man paused and then continued: "Besides, we already have a new plan here."

"New plan?" Cai Tao on the other end of the phone was a little confused.

The man didn't explain much: "I'll find out when you come back."

After saying that, the man hung up the phone. After putting away his cell phone, he opened the door of the conference room and walked in.

At this moment, in the huge conference room, there were more than a dozen people sitting at a long oval table. They were all silent, as if they were waiting for something.

If you know anyone at this moment, you will definitely be scared to the core by the lineup in this conference room.

Roche, Sanofi, AstraZeneca, Novartis, AbbVie
These are representatives from major pharmaceutical giants around the world!
If any one of them is singled out, the company behind them is a dominant pharmaceutical giant.

And now, they are all together!
The moment the man walked into the conference room, the eyes of more than a dozen people all fell on the man.

The man's face didn't show much change, but he picked up the remote control and turned on the projection, and the projector projected the content on the screen.

The first thing that caught everyone's eyes was a resume, and the photo on the resume was that of Lu Liang.

When seeing this scene, there was a commotion in the conference room.The man said with a smile at this moment: "Everyone here, there must be none of you who don't know this person, right?"

"Especially Novo and AstraZeneca."

Representatives of Novo and AstraZeneca snorted coldly at this time, seeming to be worried about what happened at that time.

The man continued: "However, I still want to introduce him to avoid any of you who don't know him."

"This person's name is Lu Liang, and he is a college student at a university in China. However, such an ordinary college student has developed a large number of drugs in just a few years."

"Have you all heard of emicizumab, sofosbuvir, PD-1/TIGHT monoclonal antibody, and second-generation tyrosinase inhibitors?"

The entire conference room was silent at this moment, everyone looked at the man, obviously they had some knowledge of these drugs.

The man smiled slightly, and then continued: "If we just develop new drugs, we won't care about it. After all, we are a free market and fair competition."

"But unfortunately, it seems that the other party has no intention of competing fairly with us."

When he said this, the man paused, and the smile on his face faded slightly.

"Novartis sells 4 bottles of Gleevec, but the other company's drug with the same effect only sells 500 bottles; the other company's drug, Imicizumab, which can replace human coagulation factor VIII, is priced at 300 bottles."

The people present couldn't help but frown, because they knew that the price of this drug was too low.

The profit from the price of this drug is so slim.

The man continued: "Because of this person, the sales of some of our key profit-making drugs in China have dropped significantly, and it is not an exaggeration to say that they have even been cut in half."

"It is estimated that our drugs will be driven out of the Chinese market soon."

There were whispers in the conference room, and the man's words made them feel a little bit uneasy.

And what the man wanted was this effect, so he continued to add insult to injury and said: "Everyone, imagine again, what will happen if these drugs enter our country?"

Dead silence.

There was dead silence in the entire conference room.

Beads of sweat began to appear on everyone's forehead, and they felt frightened and uneasy.

If they just lost China's drug market, then they could still sit still.

But the problem is that once Lu Liang's medicine enters their market, they will face a massacre.

Because they know very well that the other party's drugs can crush them in terms of price and effectiveness.

The patient's first choice is definitely to choose the other party's medicine, not the medicine produced by their company, so how can they not be in a hurry.

But soon, someone stood up and questioned: "Haven't any of you tried to cooperate?"

Everyone turned around and saw that the person speaking was a woman, and she was a representative of Bayer.

The man smiled slightly and replied: "If cooperation can be negotiated, then today's meeting will be completely unnecessary."

"Bristol Squibb has tried to discuss cooperation with the other party. You can ask them if the other party is someone who can cooperate?"

The representative of Bayer subconsciously looked in the direction of the representative of Bristol-Myers Squibb, but the representative of Bristol-Myers Squibb just sneered and said nothing.

Bayer's representative frowned slightly: "Maybe the conditions you gave are not enough."

"No, no, no." The man shook his head and stopped the Bayer representative from continuing.

The man said: "We thought so at first, so we went to talk to the other party about cooperation. We were sincere, but the other party still refused."

At this point, the man paused: "Do you think the conditions you offer to each other are better than those of our company?"

As soon as these words came out, the entire conference room fell silent for a while.

None of the conditions offered by Pfizer were accepted by the other party, which made everyone present couldn't help but weigh whether their company could offer conditions that would satisfy the other party.

Bayer's representatives couldn't help but give up the idea of ​​cooperation at this moment.

Although Bayer can be regarded as a world-renowned pharmaceutical giant, compared with Pfizer, there is still a big gap.

Pfizer can't give the other party satisfactory conditions, let alone Bayer.

The Bayer representative frowned: "Then what should we do?"

The man smiled slightly and said slowly: "Since the other party is unwilling to cooperate, we can only use some small means to force the other party to agree to cooperate."

“But to do this, we need everyone to work together.”

"Of course, if you don't want to, you can leave now."

The man looked around the conference room, but no one left. After seeing this, the man grinned: "Very good, let's discuss the next plan."

(End of this chapter)